CA2545422C — Tubulin inhibitors
Assigned to YM Biosciences Australia Pty Ltd · Expires 2015-06-02 · 11y expired
What this patent protects
Compounds of general formula (I), (II), (Ill) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (Ill) and (V) in the treatment of kinase-associated disease states is also described. Furt…
USPTO Abstract
Compounds of general formula (I), (II), (Ill) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (Ill) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (Ill) and (V). (see formula V)
Drugs covered by this patent
- Alunbrig (brigatinib) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.